ORIC Oric Pharmaceuticals (ORIC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001796280
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
112
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $510.0K priced
What the filings say about ORIC
Insiders, 180 days
-$1.7M net sold
2 sellers · 70% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.3M
3 notices
Oric Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Oric Pharmaceuticals, Inc. insiders sold a net $1.7M of stock across 70 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 22 earlier Form 4 trades (code P or S) here by this insider (1 buy, 21 sales), the last on Sep 28, 2026.
- The trade is 20.0% of the 69,828 shares held after it.
- 1 other insider sold within 30 days.
- 112 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Piscitelli Dominic sold about $189.4K of ORIC under a 10b5-1 plan on Oct 20, 2026; 1 other insider sold within 30 days and 112 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jul 24, 2026.
- The trade is 9.1% of the 38,300 shares held after it.
- 1 other insider sold within 30 days.
- 112 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Heyman Richard A. sold about $45.2K of ORIC under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 112 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jul 24, 2026.
- The trade is 1.6% of the 203,472 shares held after it.
- 1 other insider sold within 30 days.
- 112 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Heyman Richard A. sold about $41.3K of ORIC under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 112 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (1 buy, 20 sales), the last on Sep 24, 2026.
- The trade is 19.2% of the 69,828 shares held after it.
- 1 other insider sold within 30 days.
- 112 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Piscitelli Dominic sold about $181.3K of ORIC under a 10b5-1 plan on Sep 28, 2026; 1 other insider sold within 30 days and 112 funds added in the latest 13F quarter.Context
- 19 earlier Form 4 trades (code P or S) here by this insider (1 buy, 18 sales), the last on Aug 26, 2026.
- The trade is 0.1% of the 70,328 shares held after it.
- 1 other insider sold within 30 days.
- 112 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Piscitelli Dominic sold about $1.4K of ORIC under a 10b5-1 plan on Sep 24, 2026; 1 other insider sold within 30 days and 112 funds added in the latest 13F quarter.70 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.7M over 180 days
-$1.5M over 90 days
below 68% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
112 funds bought in last quarter
more than 73% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
18.4% of the float short (float per yahoo 2026-10-26) · 9.8 days to cover · settled 2026-09-30
more than 87% of Pharma & Biotech
What changed in the last 30 days
Oct 21Chief Financial Officer Piscitelli Dominic sold $370.6K under a 10b5-1 plan (2 trades, Sep 28 to Oct 20)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Director Heyman Richard A. sold $86.5K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Director Richard A, Heyman filed to sell $109.1K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Director Richard A, Heyman filed to sell $102.4K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch ORIC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+9.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ORIC: institutional holders (13F)
13F holdings, latest reported quarter
7,162,637 sh
$77.6M
6,823,973 sh
$73.9M
6,728,116 sh
$72.9M
5,126,762 sh
$55.5M
4,894,000 sh
$53.0M
Congress trades in ORIC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ORIC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Richard A, Heyman
Filed 2026-10-01
$102.4K
Richard A, Heyman
Filed 2026-10-01
$109.1K
Dominic Piscitelli
Filed 2026-08-26
$3.1M
Richard A, Heyman
Filed 2026-07-06
$76.8K
Richard A, Heyman
Filed 2026-07-06
$84.0K
ORIC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$416.1K position · as of 2026-07-31
0.9%
Victory RS Small Cap Growth Fund
$2.8M position · as of 2026-06-30
0.7%
Franklin Biotechnology Discovery Fund
$7.3M position · as of 2026-07-31
0.6%
Meridian Contrarian Fund
$4.0M position · as of 2026-06-30
0.6%
Eventide Healthcare & Life Sciences Fund
$10.3M position · as of 2026-06-30
0.6%
Victory RS Science & Technology Fund
$1.0M position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
6
Phase 1
2 active
1
Phase 3
1 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Jacob M. Chacko, M.D.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.6M
$5.7M
$2.3M
-11%
n/a
2024
$5.3M
$4.3M
$2.2M
-12%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.7M sold by insiders over 180 days, 112 funds added last quarter, $3.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ORIC financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ORIC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ORIC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$112.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ORIC
| FY Dec 2025 | -$111.7M |
| FY Dec 2024 | -$113.8M |
| FY Dec 2023 | -$86.5M |
| FY Dec 2022 | -$77.2M |
| FY Dec 2021 | -$60.5M |
| Jun 2026 | -$32.0M |
| Mar 2026 | -$32.4M |
| Dec 2025 | -$22.7M |
| Sep 2025 | -$25.1M |
| Jun 2025 | -$30.9M |
| Mar 2025 | -$32.9M |
| Dec 2024 | -$28.3M |
| Sep 2024 | -$29.2M |
At each fiscal year end
Single quarter
Debt to equity
0.03x
long-term debt only, 2021-12-31 (54 months older than the period end); equity 2026-06-30
Debt to equity ORIC
| FY Dec 2025 | 0.03x |
| FY Dec 2024 | 0.04x |
| FY Dec 2023 | 0.05x |
| FY Dec 2022 | 0.05x |
| FY Dec 2021 | 0.04x |
| Jun 2026 | 0.03x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.03x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.05x |
| Dec 2024 | 0.04x |
| Sep 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-10.63x
TTM operating cash flow over long-term debt only, 2021-12-31 (54 months older than the period end)
Cash flow to debt ORIC
| FY Dec 2025 | -10.57x |
| FY Dec 2024 | -10.73x |
| FY Dec 2023 | -8.16x |
| FY Dec 2022 | -7.16x |
| FY Dec 2021 | -5.67x |
| Jun 2026 | -10.63x |
| Mar 2026 | -10.56x |
| Dec 2025 | -10.57x |
| Sep 2025 | -11.10x |
| Jun 2025 | -11.45x |
| Mar 2025 | -10.95x |
| Dec 2024 | -10.73x |
| Sep 2024 | -10.37x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-39.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ORIC
| FY Dec 2025 | -41.3% |
| FY Dec 2024 | -54.7% |
| FY Dec 2023 | -45.1% |
| FY Dec 2022 | -36.0% |
| FY Dec 2021 | -28.0% |
| Jun 2026 | -39.8% |
| Mar 2026 | -42.6% |
| Dec 2025 | -41.3% |
| Sep 2025 | -39.7% |
| Jun 2025 | -43.8% |
| Mar 2025 | -48.5% |
| Dec 2024 | -54.7% |
| Sep 2024 | -46.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-37.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ORIC
| FY Dec 2025 | -37.9% |
| FY Dec 2024 | -48.6% |
| FY Dec 2023 | -40.3% |
| FY Dec 2022 | -32.7% |
| FY Dec 2021 | -26.3% |
| Jun 2026 | -37.4% |
| Mar 2026 | -39.8% |
| Dec 2025 | -37.9% |
| Sep 2025 | -36.9% |
| Jun 2025 | -40.6% |
| Mar 2025 | -44.8% |
| Dec 2024 | -48.6% |
| Sep 2024 | -41.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital ORIC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-43.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ORIC
| FY Dec 2025 | -44.8% |
| FY Dec 2024 | -59.4% |
| FY Dec 2023 | -47.8% |
| FY Dec 2022 | -35.6% |
| FY Dec 2021 | -27.5% |
| Jun 2026 | -43.8% |
| Mar 2026 | -46.5% |
| Dec 2025 | -44.8% |
| Sep 2025 | -42.8% |
| Jun 2025 | -46.9% |
| Mar 2025 | -52.3% |
| Dec 2024 | -59.4% |
| Sep 2024 | -50.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ORIC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.3B
market value at close 2026-10-23 on 2026-07-27 shares, plus long-term debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
Enterprise value ORIC
| FY Dec 2025 | $761.5M |
| FY Dec 2024 | $520.6M |
| FY Dec 2023 | $489.0M |
| FY Dec 2022 | $176.8M |
| FY Dec 2021 | $363.4M |
| Jun 2026 | $1.1B |
| Mar 2026 | $1.2B |
| Dec 2025 | $761.5M |
| Sep 2025 | $1.1B |
| Jun 2025 | $656.2M |
| Mar 2025 | $357.5M |
| Dec 2024 | $520.6M |
| Sep 2024 | $689.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-8.2%
TTM free cash flow over market value at close 2026-10-23
FCF yield ORIC
| FY Dec 2025 | -14.0% |
| FY Dec 2024 | -20.0% |
| FY Dec 2023 | -17.2% |
| FY Dec 2022 | -33.1% |
| FY Dec 2021 | -10.4% |
| Jun 2026 | -10.0% |
| Mar 2026 | -8.7% |
| Dec 2025 | -14.0% |
| Sep 2025 | -10.1% |
| Jun 2025 | -16.8% |
| Mar 2025 | -29.4% |
| Dec 2024 | -20.0% |
| Sep 2024 | -15.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ORIC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M |
| Net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M |
| EPS (diluted) | -1.47 | -1.83 | -1.96 | -2.25 |
| Operating cash flow | -$111.0M | -$112.7M | -$85.7M | -$75.1M |
| Cash | $45.7M | $59.4M | $23.4M | $66.8M |
SEC XBRL, fiscal years, as known on 2026-10-27
ORIC Stock Sonar score 5/7 axes
Find similar shapesCompareORIC ranks highest on institutional and government (73rd percentile) and profitability (57th), and lowest on risk and compliance (18th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ORIC filings, in plain words
Are Oric Pharmaceuticals insiders buying or selling ORIC?
In the 180 days to 2026-10-27, Oric Pharmaceuticals insiders were net sellers, a net $1.7M across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of ORIC?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $3.3M of stock; the latest, by Richard A, Heyman, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-27, Oric Pharmaceuticals insiders were net sellers of ORIC, a net $1.7M across purchases and sales reported on Form 4 by 2 sellers. 70% of the 10 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $3.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
